Relatively few attempts to mutagenize animal viruses by various agents have been reported (see 2). Quantitative data on the effectiveness of the mutagens are scarce. In our laboratory, the use of different methods (nitrous acid, hydroxylamine, nitrosoguanidine) to induce significant levels of mutation in arboviruses has been only partially successful. Recently, a relatively new cytidine analogue, 5-azacytidine (5-AzaC) was Most experiments were performed with strain T, the attenuated, small-plaque variant derived from the large plaque-forming Trinidad strain of Venezuelan equine encephalitis (V) virus (1). 5-AzaC (Calbiochem, Los Angeles, Calif.), prepared as 100 times concentrated aqueous stocks, membrane filtered (Millipore Corp., Bedford, Mass.), and stored frozen [-70 F (-56.7 C)] for up to 4 months, was thawed prior to use for each experiment. The mutagen was usually incorporated in the minimal medium described by Zebovitz (5), which contains histidine and cystine as the only additives to a buffered, basal salt solution. This medium was used as a liquid overlay for chick embryo (CE) monoalyer cultures held at 37 C after infection with virus. Supernatant fluids harvested at 24 hr were assayed for plaque-forming unit (PFU) titer and for the frequency of large plaques among survivors. Assay was performed on 24-hr CE monolayers incubated at 37 C under a 5% CO2 atmosphere for 2 days before staining and scoring.
Relatively few attempts to mutagenize animal viruses by various agents have been reported (see 2) . Quantitative data on the effectiveness of the mutagens are scarce. In our laboratory, the use of different methods (nitrous acid, hydroxylamine, nitrosoguanidine) to induce significant levels of mutation in arboviruses has been only partially successful. Recently, a relatively new cytidine analogue, 5-azacytidine (5-AzaC) was reported by Sorm et al. (4) . It is known to be inhibitory for growth, and one of its proposed modes of action is that it is incorporated into ribonucleic acid (RNA), which subsequently disintegrates. Most experiments were performed with strain T, the attenuated, small-plaque variant derived from the large plaque-forming Trinidad strain of Venezuelan equine encephalitis (V) virus (1). 5-AzaC (Calbiochem, Los Angeles, Calif.), prepared as 100 times concentrated aqueous stocks, membrane filtered (Millipore Corp., Bedford, Mass.), and stored frozen [-70 F (-56.7 C)] for up to 4 months, was thawed prior to use for each experiment. The mutagen was usually incorporated in the minimal medium described by Zebovitz (5), which contains histidine and cystine as the only additives to a buffered, basal salt solution. This medium was used as a liquid overlay for chick embryo (CE) monoalyer cultures held at 37 C after infection with virus. Supernatant fluids harvested at 24 hr were assayed for plaque-forming unit (PFU) titer and for the frequency of large plaques among survivors. Assay was performed on 24-hr CE monolayers incubated at 37 C under a 5% CO2 atmosphere for 2 days before staining and scoring.
Concentrations of 5-AzaC as low as 5 ,ug/ml significantly increased the frequency of large plaques in the T strain population when compared with controls lacking 5-AzaC. To maximize the effect, concentrations of 10 or 25 ug/ml were usually used. Treatment with 25 pg/ml under the conditions just described gave a virus titer approximately 100-fold lower than that of untreated controls. Figure 1 is representative of control and treated populations. The results of several experiments (Table 1 ) using 25 pg of 5-AzaC per ml showed that the induced large-plaque frequency among survivors varied from 77-to 220-fold higher than that of untreated controls.
To test whether the observed large plaques represented unstable phenotypic variants or stable genotypes, random large-plaque isolates were cloned and then checked for plaque size heterogeneity. Of the several isolates tested, all were true large-plaque mutants rather than phenotypic variants. Tests for sensitivity of the small-and large-plaque variants to the inducing agent (5-AzaC), as an inhibitor during growth in CE cells, showed no significant differences between them.
In reconstruction experiments, cultures were inoculated with seeds of stocks made from several independently isolated large-and small-plaque survivors of 5-AzaC treatment, each in various inoculum ratios. In these experiments, each virus alone or in mixtures showed similar inhibition of growth by 25 pg of 5-AzaC per ml (5 to 8.4% of normal). The increased frequency of large plaques found in the 5-AzaC-treated cultures could not be attributed to selection. Another type of reconstruction experiment in vitro, in which the viruses were treated (alone or in mixtures) with the drug in the absence of cells, also showed no inactivation by 5-AzaC in our system.
Characterization Initial studies on the mechanism of 5-AzaC action involving the addition of various nucleic acid precursors as antagonists to this potent analogue are shown in Table 2 . These results showed that cytidine and uridine, when added immediately after viral adsorption (time 0), were both good antagonists to 5-AzaC action, but deoxycytidine gave only partial reversal of both inhibition and mutation. Neither uracil nor thymidine at concentrations up to 200 mg/ml reversed 5-AzaC lethality for strain T. Cytosine was also ineffective. Experiments in which inhibitor (10 Ag of 5-AzaC/ ml) and antagonist (200 pg of uridine/ml) were added at various times postinfection showed that Further studies on the mechanism of 5-AzaC action on arbovirus synthesis will be reported in detail in future publications.
